IMUC
$0.03
Immunocellular Thera
$.00
(1.15%)
IMUC
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Monday
Sep 23
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when IMUC reports earnings?
Beat
Meet
Miss

Where is IMUC's stock price going from here?
Up
Flat
Down
Stock chart of IMUC
Analysts
Summary of analysts' recommendations for IMUC
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.
Peers
IncyteAlexion PharmaceuticalsCharles River Laboratories InternationalExact SciencesCoherus BiosciencesExelixisLuminex